NYMOX PHARMACEUTICAL CORPORATION

NYMOX PHARMACEUTICAL CORPORATION

March 24, 2005 10:59 ET

New Medicare Decision to Cover Smoking Cessation Good News for Nymox


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX PHARMACEUTICAL CORPORATION

NASDAQ SYMBOL: NYMX

MARCH 24, 2005 - 10:59 ET

New Medicare Decision to Cover Smoking Cessation Good
News for Nymox

MAYWOOD, N.J.--(CCNMatthews - Mar 24, 2005) -

Nymox (NASDAQ:NYMX) NicAlert™ Product Offers On-Site, Cost-Effective
Means of Testing for Tobacco Use

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) welcomes the news that
Medicare will cover smoking cessation counseling services for millions
of its beneficiaries who smoke and have been diagnosed with a smoking
related disease or are taking certain drugs affected by tobacco use. The
Centers for Medicare and Medicaid Services (CMS) noted that researchers
estimated that smoking accounted for about 10% of the total costs of the
Medicare program in 1997 or about $20.5 billion.

Nymox's NicAlert™ product provides a proven, easy-to-use, on-site
means of determining the level of an individual's use of or exposure to
tobacco products. NicAlert™ has received U.S. FDA clearance for
medical use for determining an individual's exposure to tobacco
products.

The CMS coverage decision follows the earlier, widely endorsed U.S.
Public Health Service clinical practice guideline, Treating Tobacco Use
and Dependence (JAMA 2000; 283:3244-54), which recommends that
physicians should routinely assess, review and document the smoking
status of every patient. This recommendation has been adopted by the
American Medical Association, the American Heart Association, the
American Academy of Family Physicians, the American Diabetes Association
and other medical associations. Studies have shown that a significant
percentage of patients at risk do not always truthfully report their
smoking status.

Getting smokers to quit has been identified by governments and employers
as offering not only important health benefits but also improved
productivity and reduced healthcare costs. A U.S. Department of Health
and Human Services (HHS) report entitled "Prevention Makes Common
'Cents'" found that covering treatments to help employees quit smoking
offers substantial savings for employers in the costs of treating
smoking-related illness. Several dozen major corporations currently
offer coverage for smoking cessation programs to millions of employees
and their dependents as part of a comprehensive cancer screening and
prevention program.

NicAlert™ uses powerful, one-step patented technology to measure the
level of cotinine, a metabolite of nicotine, in urine. Cotinine is
widely accepted and commonly used in medical research and public health
studies to determine the extent of tobacco product use or exposure.
NicAlert™ is a quick, accurate and easy to use test that can be done
almost anywhere, including at home, the workplace or school and that
requires no instruments to use.

NicAlert™ has been successfully used in public health initiatives
(such as, for example, smoking cessation programs and quit-smoking
contests) in the U.S., Switzerland and Canada. Studies have shown that
NicAlert™ can help smokers quit. A large European clinical trial
found significant smoking reduction over the four-month trial period
when nicotine replacement therapy (NRT) was combined with individual
cotinine levels as measured by NicAlert™.

Independent studies have found the technology employed in NicAlert™
to be an accurate, rapid and cost-effective means of confirming smoking
status. One study, "Validating a Dipstick Method for Detecting Recent
Smoking," Cancer Epidemiology, Biomarkers & Prevention (2002;
11:1123-1125) examined the smoking status of patients at a cancer clinic
and found that the results obtained using Nymox's tobacco product
exposure test had an "excellent agreement" with state-of-the-art
sophisticated laboratory measurements but at a substantially lower cost
(over 90% less). Another peer-reviewed study, "The Accuracy of
Self-Reported Smoking Status Assessed by Cotinine Test Strips," Nicotine
& Tobacco Research (2002; 4:305-9) found Nymox's product to be "an
inexpensive and rapid method to routinely bio-chemically confirm smoking
status at a clinical visit." The authors described the Nymox product as
a "simple, inexpensive and rapid measure to immediately confirm smoking
status in field settings."

The U.S. Surgeon General, the Centers for Disease Control and Prevention
(CDC), the World Health Organization (WHO) and many other public health
organizations have targeted tobacco use as the single most preventable
cause of premature death today. The CDC estimates that smoking causes
over 440,000 premature deaths annually in the United States and creates
an economic loss of over $150 billion a year. Worldwide, the WHO
estimates that tobacco use and exposure currently kills 4.9 million
people a year and that this death toll will rise to 10 million a year by
2020.

In February 2005, the WHO Framework Convention on Tobacco Control came
into effect in 57 countries. The treaty requires the adoption and
implementation of measures to reduce exposure to second hand smoke, to
diagnose tobacco dependence and to promote tobacco use cessation.

Nymox also offers TobacAlert™, which is for non-medical uses and can
detect second-hand smoke exposure. TobacAlert™ is available at
approximately 5,400 CVS/pharmacy® stores across the U.S. as well as
online at www.cvs.com. More information about TobacAlert™ is
available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com